Baxter International Inc. (BAX) Valuation
Historical valuation analysis based on 1280 data points (2021-09-13 to 2026-10-16)
Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative se...
Baxter International Inc. (BAX) currently trades at a P/E ratio of 159.38 (historical range: 6.19–179.65, median: 30.51), placing it at the 92th percentile — expensive relative to its history, P/S ratio of 1.14 (range: 0.74–3.65, 20th percentile — below its historical average), EV/EBITDA of 22.11 (range: 7.95–114.64, 30th percentile).
Over the historical period (2021-09-13 to 2026-10-16), Baxter International Inc.'s P/E ratio has expanded by 232% over the observed period (from an average of 24.6 to 81.6).
Baxter International Inc. trades near its historical valuation range, with most metrics close to their median levels.
Historical Valuation Metrics
| Metric | Current | Median | %ile | Assessment |
|---|---|---|---|---|
| P/E Ratio | 159.38 | 30.51 | 92th | expensive relative to its history |
| P/S Ratio | 1.14 | 1.42 | 20th | below its historical average |
| EV/EBITDA | 22.11 | 35.07 | 30th | below its historical average |
| FCF Yield | 7.12% | 3.49% | 96th | cheap relative to its history |
Baxter International Inc. (BAX) Valuation & P/E History
Baxter International Inc. (BAX) is a US-listed stock operating in the Healthcare sector, specifically the Surgical & Medical Instruments & Apparatus industry currently trading at $25.30 with a market capitalization of $13.1 billion. This page provides historical valuation analysis for BAX based on 1280 data points covering 2021-09-13 to 2026-10-16. The P/E ratio of 159.38 is above the historical median of 30.51, placing BAX at the 92th percentile of its valuation range. The P/S ratio of 1.14 compares to a median of 1.42.
BAX Valuation Metrics & Historical Range
The valuation table above shows Baxter International Inc.'s current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether BAX is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests BAX is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Baxter International Inc..
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is BAX Overvalued or Undervalued?
Baxter International Inc. trades near its historical valuation range, with most metrics close to their median levels. The overall valuation percentile of 47 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive BAX is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full BAX analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.BAX trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.